features: Myelodysplastic Syndromes

VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…

VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

VJHemOnc is excited to bring you the latest updates from research investigating the treatment and management of myeloid malignancies, as…

A session with myelodysplastic syndromes (MDS) expert John Bennett who discusses MDS diagnosis and prognosis.

Watch the full ASH 2020 MDSF Virtual Symposium on demand

  VJHemOnc brings you roundtable discussions with leading hematological experts in myeloma, AML, CLL, ALL, lymphoma, MDS and MPNs.

VJHemOnc is proud to present the SOHO Italy 2020 Virtual Meeting, which took place on the 22nd-24th of September 2020.

In this session, Amer Zeidan, John Mascarenhas, Jan Bewersdorf & Rory Shallis discuss and debate the special considerations for managing…

Published in Blood, a special report has proposed a new, distinct subtype of myelodysplastic syndromes (MDS) based on the presence…

Kiadis Pharma have filed the first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for…

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and curative therapy for a large number of hematologic malignancies. Adverse…